EPS for Soleno Therapeutics, Inc. (SLNO) Expected At $-0.30

August 9, 2018 - By Mark Babin

Analysts expect Soleno Therapeutics, Inc. (NASDAQ:SLNO) to report $-0.30 EPS on August, 10.They anticipate $0.00 EPS change or 0.00 % from last quarter’s $-0.3 EPS. After having $-0.17 EPS previously, Soleno Therapeutics, Inc.’s analysts see 76.47 % EPS growth. It closed at $2.7 lastly. It is down 41.31% since August 9, 2017 and is downtrending. It has underperformed by 53.88% the S&P500.

Soleno Therapeutics, Inc. focuses on the development and commercialization of novel therapeutics for the treatment of rare diseases. The company has market cap of $53.38 million. The company's lead candidate, diazoxide choline controlled-release , a once-daily oral tablet for the treatment of Prader-Willi Syndrome (PWS), is entering into Phase II/III clinical development. It currently has negative earnings. It also markets medical devices, including the CoSense End-Tidal Carbon Monoxide (ETCO) monitor, which measures ETCO and is used by hospitals to detect hemolysis in newborns; and NeoPip T-piece resuscitator and related consumables, which deliver consistent pre-set inspiratory pressure and positive end-expiratory pressures, as well as temperature probes, scales, surgical tables, and patient surfaces.

More important recent Soleno Therapeutics, Inc. (NASDAQ:SLNO) news were published by: Benzinga.com which released: “50 Biggest Movers From Yesterday” on July 31, 2018, also Benzinga.com published article titled: “28 Stocks Moving In Monday’s Pre-Market Session”, Nasdaq.com published: “Soleno Therapeutics Receives Fast Track Designation from FDA for DCCR for Treatment of Prader-Willi Syndrome” on July 30, 2018. More interesting news about Soleno Therapeutics, Inc. (NASDAQ:SLNO) was released by: Benzinga.com and their article: “Mid-Morning Market Update: Markets Down; Caterpillar Tops Q2 Expectations” with publication date: July 30, 2018.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.